Hi Chook,
I have thought about Acadia side of the deal lately. Can anyone who has a model setup punch Acadia rough figures in.
I see our side produces some very high numbers, but theirs would be even higher, minus more costs obviously. In a market that values bio's apparently much better than ours, it's hard to see why they are still in the red post FDA approval.
Moonsoon Briefing Thurs 20 April, page-54
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.12 |
Change
-0.270(1.39%) |
Mkt cap ! $2.440B | |||
| Open | High | Low | Value | Volume |
| $19.55 | $19.65 | $18.88 | $3.472M | 181.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 129 | $19.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.12 | 87 | 6 |
View Market Depth
| Last trade - 12.07pm 31/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |